Tailored supplemental screening for breast cancer: What now and what next?

American Journal of Roentgenology

Volumn 192, Issue 2, 2009, Pages 390-399

  Berg, Wendie A ^a,b  

^a Naviscan Inc

^b Johns Hopkins Green Spring   (United States)

Author keywords

Breast cancer screening; Breast imaging; Breast MRI; Breast sonography; Gamma imaging; Mammography; PET

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COWDEN SYNDROME; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GROUPS BY AGE; HEALTH CARE POLICY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEUTZ JEGHERS SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RADIATION EXPOSURE; RADIOLOGIST; REVIEW; RISK ASSESSMENT; SCINTIMAMMOGRAPHY; THERMOGRAPHY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GAMMA CAMERAS; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; ULTRASONOGRAPHY, MAMMARY;

EID: 59349097209     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.08.1706     Document Type: Review

References (79)

1. Saslow D, Boetes C, Burke W, et al.; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75-89 [Erratum in CA Cancer J Clin 2007; 57:185]
2. Evans DG, Howell A. Breast cancer risk-assessment models. Breast Cancer Res 2007; 9:213
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388
4. de la Hoya M, Díez O, Pérez-Segura P, et al. Pretest prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet 2003; 40:503-510
5. Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008; 299:2151-2163
6. Surveillance, epidemiology, and end results Website. SEER stat facts sheets: breast cancer. seer. cancer.gov/statfacts/html/breast.html. Accessed August 13, 2008
7. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358:1389-1399
8. Dershaw DD. Mammographic screening of the high-risk woman. Am J Surg 2000; 180:288-289
9. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002; 158:220-235
10. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21:2397-2406
11. National Comprehensive Cancer Network. National clinical practice guidelines in oncology genetic/familial high-risk assessment: breast and ovarian. Version 1.2008. Published May 16, 2008. www.nccn.org/professionals/ physician-gls/PDF/genetics-screening.pdf. Accessed October 26, 2008
12. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469-8476
13. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401-1408
14. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20:2701-2712
15. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23:1111-1130 [Erratum in Stat Med 2005; 24:156]
16. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008; 98:1457-1466
17. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-1886
18. Adams-Campbell LL, Makambi KH, Palmer JR, Rosenberg L. Diagnostic accuracy of the Gail model in the Black Women's Health Study. Breast J 2007; 13:332-336
19. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994; 73:643-651
20. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:347-360
21. National Comprehensive Cancer Network. National clinical practice guidelines in oncology: breast cancer screening and diagnosis. Version 1.2008. Published April 15, 2008. www.nccn.org/professionals/physician-gls/PDF/breast- screening.pdf. Accessed October 26, 2008
22. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19:924-930
23. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20:1260-1268
24. Palacios J, Robles-Frias MJ, Castilla MA, Lopez-Garcia MA, Benitez J. The molecular pathology of hereditary breast cancer. Pathobiology 2008; 75:85-94
25. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93:1633-1637
26. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997; 79:1203-1210
27. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979-4990
28. National Comprehensive Cancer Network. National clinical practice guidelines in oncology: invasive breast cancer. 2008;1 Version 2.2008. Published January 28, 2008. www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed October 26, 2008
29. Badgwell BD, Giordano SH, Duan ZZ, et al. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 2008; 26:2482-2488
30. Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J. Is screening mammography effective in elderly women? Am J Med 2000; 108:112-119
31. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750-2756
32. Pisano ED, Gatsonis C, Hendrick E, et al.; Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005; 353:1773-1783 [Erratum in N Engl J Med 2006; 355:1840]
33. Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. Radiology 2007; 244:708-717
34. Tosteson AN, Stout NK, Fryback DG, et al. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 2008; 148:1-10
35. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996
36. Helvie MA, Bailey JE, Roubidoux MA, et al. Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology 2002; 224:211-216
37. Lee JM, Georgian-Smith D, Gazelle GS, et al. Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology 2008; 248:398-405
38. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 2004; 42:793-806
39. Hagen AI, Kvistad KA, Maehle L, et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007; 16:367-374
40. Hartman AR, Daniel BL, Kurian AW, et al. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer 2004; 100:479-489
41. Kriege M, Brekelmans CT, Boetes C, et al. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer 2006; 106:2318-2326
42. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:1769-1778
43. Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103:1898-1905
44. Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007; 244:381-388
45. Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007; 242:698-715
46. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292:1317-1325
47. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148:671-679
48. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427-437
49. Murphy CD, Lee JM, Drohan B, et al. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. Cancer 2008; 113:3116-3120
50. National Cancer Institute Website. Breast cancer risk assessment tool: an interactive tool for measuring the risk of invasive breast cancer. www.cancer.gov/bcrisktool/Default.aspx. Accessed August 1, 2008
51. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003; 40:807-814
52. National Collaborating Centre for Primary Care Website. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care - update. Published July 2006. www.nice.org.uk/nicemedia/pdf/CG41fullguidance.pdf. Accessed August 2, 2008
53. Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006; 295:2374-2384
54. Bigenwald RZ, Warner E, Gunasekara A, et al. Is mammography adequate for screening women with inherited BRCA mutations and low breast density? Cancer Epidemiol Biomarkers Prev 2008; 17:706-711
55. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol 2008; 5:45-52
56. Bassett LW, Dhaliwal SG, Eradat J, et al. National trends and practices in breast MRI. AJR 2008; 191:332-339
57. Stomper PC, D'Souza DJ, DiNitto PA, Arredondo MA. Analysis of parenchymal density on mammograms in 1,353 women 25-79 years old. AJR 1996; 167:1261-1265
58. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356:227-236
59. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004; 230:29-41
60. Kopans DB. Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk. Radiology 2008; 246:348-353
61. Berg WA, Campassi C, Langenberg P, Sexton MJ. Breast imaging reporting and data system: inter-and intraobserver variability in feature analysis and final assessment. AJR 2000; 174:1769-1777
62. Berg WA. Supplemental screening sonography in dense breasts. Radiol Clin North Am 2004; 42:845-851, vi
63. Corsetti V, Ferrari A, Ghirardi M, et al. Role of ultrasonography in detecting mammographically occult breast carcinoma in women with dense breasts. Radiol Med (Torino) 2006; 111:440-448
64. Corsetti V, Houssami N, Ferrari A, et al. Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer 2008; 44:539-544
65. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225:165-175
66. Buchberger W, Niehoff A, Obrist P, DeKoekkoek-Doll P, Dunser M. Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR 2000; 21:325-336
67. Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR 2003; 181:177-182
68. Gordon PB, Goldenberg SL. Malignant breast masses detected only by ultrasound: a retrospective review. Cancer 1995; 76:626-630
69. Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 2001; 221:641-649
70. Leconte I, Feger C, Galant C, et al. Mammography and subsequent whole-breast sonography of non-palpable breast cancers: the importance of radiologic breast density. AJR 2003; 180:1675-1679
71. Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 2008; 247:651-657
72. Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology 2005; 237:274-280
73. O'Connor MK, Phillips SW, Hruska CB, Rhodes DJ, Collins DA. Molecular breast imaging: advantages and limitations of a scintimammographic technique in patients with small breast tumors. Breast J 2007; 13:3-11
74. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J 2006; 12:309-323
75. Moskowitz M, Milbrath J, Gartside P, Zermeno A, Mandel D. Lack of efficacy of thermography as a screening tool for minimal and stage I breast cancer. N Engl J Med 1976; 295:249-252
76. Brenner RJ, Parisky Y. Alternative breast-imaging approaches. Radiol Clin North Am 2007; 45:907-923, viii
77. Lindfors KK, Boone JM, Nelson TR, Yang K, Kwan AL, Miller DF. Dedicated breast CT: initial clinical experience. Radiology 2008; 246:725-733
78. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25:1329-1333
79. American Cancer Society Website. Breast cancer facts and figures 2007-2008. www.cancer.org/downloads/STT/BCFF-Final.pdf. Accessed August 20, 2008